Guven DC - Search Results

1

The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors.

Guven DC, Ozbek DA, Sahin TK, Kavgaci G, Aksun MS, Erul E, Yildirim HC, Chalabiyev E, Cebroyilov C, Yildirim T, Dizdar O, Aksoy S, Yalcin S, Kilickap S, Erman M, Arici M. Guven DC, et al. Anticancer Drugs. 2023 Jul 1;34(6):783-790. doi: 10.1097/CAD.0000000000001463. Epub 2022 Dec 19. Anticancer Drugs. 2023. PMID: 36729111

2

Noninferiority for Short-HER or short-chemotherapy?

Aktas BY, Guven DC, Dizdar O. Aktas BY, et al. Among authors: guven dc. Ann Oncol. 2019 Jan 1;30(1):147. doi: 10.1093/annonc/mdy491. Ann Oncol. 2019. PMID: 30395162 Free article. No abstract available.

3

All Positives May Not Be the Same in Pancreatic Cancer: Lessons Learned From the Past.

Ceylan F, Guven DC, Sahin TK, Ozbek DA, Dizdar O. Ceylan F, et al. Among authors: guven dc. Am J Clin Oncol. 2020 Sep;43(9):676. doi: 10.1097/COC.0000000000000723. Am J Clin Oncol. 2020. PMID: 32889840 No abstract available.

4

The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy.

Guven DC, Kavgaci G, Aktepe OH, Yildirim HC, Sahin TK, Aksoy S, Erman M, Kilickap S, Yalcin S. Guven DC, et al. J Oncol Pharm Pract. 2022 Jun;28(4):785-793. doi: 10.1177/10781552211012038. Epub 2021 Apr 20. J Oncol Pharm Pract. 2022. PMID: 33878976

5

Lower prognostic nutritional index is associated with poorer survival in patients receiving immune checkpoint inhibitors.

Guven DC, Aktepe OH, Taban H, Aktas BY, Guner G, Yildirim HC, Sahin TK, Aksun MS, Dizdar O, Aksoy S, Erman M, Yalcin S, Kilickap S. Guven DC, et al. Biomark Med. 2021 Sep;15(13):1123-1130. doi: 10.2217/bmm-2020-0674. Epub 2021 Aug 16. Biomark Med. 2021. PMID: 34397271

6

Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards.

Guven DC, Eroglu I, Ismayilov R, Ulusoydan E, Aktepe OH, Telli Dizman G, Arik Z, Dizdar O, Unal S, Metan G, Kertmen N. Guven DC, et al. J Oncol Pharm Pract. 2022 Dec;28(8):1807-1811. doi: 10.1177/10781552211043836. Epub 2021 Sep 30. J Oncol Pharm Pract. 2022. PMID: 34590515 Free PMC article.

7

Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review.

Guven DC, Sahin TK, Kilickap S, Uckun FM. Guven DC, et al. Front Oncol. 2021 Nov 4;11:759108. doi: 10.3389/fonc.2021.759108. eCollection 2021. Front Oncol. 2021. PMID: 34804957 Free PMC article.

8

Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.

Guven DC, Sahin TK, Akın S, Uckun FM. Guven DC, et al. Oncologist. 2022 Apr 5;27(4):e357-e361. doi: 10.1093/oncolo/oyac032. Oncologist. 2022. PMID: 35274729 Free PMC article.

9

SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research.

Guven DC, Sahin TK, Akın S, Uckun FM. Guven DC, et al. Oncologist. 2022 Nov 3;27(11):e917-e918. doi: 10.1093/oncolo/oyac173. Oncologist. 2022. PMID: 36005823 Free PMC article.

10

The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study.

Güven DC, Yıldırım HÇ, Erul E, Şahin TK, Çakır İY, Aktepe OH, Kertmen N, Dizdar Ö, Aksoy S. Güven DC, et al. Turk J Med Sci. 2022 Oct;52(5):1551-1558. doi: 10.55730/1300-0144.5495. Epub 2022 Oct 19. Turk J Med Sci. 2022. PMID: 36422490 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

143 results

Search Page

Filters